Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643197 | 1.00 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL29799847 | 1.00 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL1643200 | 1.00 | GNRHR (1.00) | GNRHRCYP3A4 | |
| Hydrochloric Acid SCHEMBL29816173 | 0.99 | GNRHR (0.98) | GNRHRCYP3A4 | |
| Oxalic Acid SCHEMBL29816324 | 0.97 | GNRHR (0.94) | GNRHRCYP3A4 | |
| SCHEMBL5758028 | 0.92 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL5758037 | 0.92 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL30299007 | 0.92 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL5758034 | 0.92 | GNRHR (1.00) | GNRHRCYP3A4 | |
| Salicylic Acid SCHEMBL28522582 | 0.92 | GNRHR (0.85) | GNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-12-12 | — | — | US | disclosed |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-12-12 | — | — | US | disclosed |
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-03-09 | — | — | US | disclosed |
| US-11459305-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2021130776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2021-07-01 | — | — | WO | disclosed |
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20190218191-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20180346428-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20170320836-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9382214-B2 | Processes for the preparation of uracil derivatives | Neurocine Biosciences, Inc. (US) | 2016-07-05 | — | — | US | disclosed |
| US-8765948-B2 | Processes for the preparation of uracil derivatives | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. | 2011-04-28 | — | — | US | disclosed |
| WO-2009062087-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | NEUROCRINE BIOSCIENCES, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-1660091-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7329669-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1646389-A1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050043338-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-20050038057-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (CA) | 2005-02-17 | — | — | US | disclosed |
| WO-2005007165-A1 | PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255387-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885 |
| US-20050043338-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1232/4885 |
| US-20190218191-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885 |
| US-20180346428-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885 |
| US-20050038057-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1565/4885 |
| US-20110098472-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885 |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | ELP1, BPNT1, EPX | GNRHR 4622/4885CYP3A4 3904/4885 |
| US-20170320836-A1 | PROCESSES FOR THE PREPARATION OF URACIL DERIVATIVES | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885 |
| US-20230072265-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS | BPNT1, GABRA6, GABRA1 | GNRHR 4217/4885CYP3A4 63/4885 |
| US-11459305-B2 | Processes for the preparation of uracil derivatives | GNRHR, FSHR, GHRHR | GNRHR 1/4885CYP3A4 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.